Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.
about
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza VaccinesStructure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactionsThe structure of cytomegalovirus immune modulator UL141 highlights structural Ig-fold versatility for receptor bindingGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveImmunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.Molecular basis of live-attenuated influenza virus.The NB protein of influenza B virus is not necessary for virus replication in vitro.Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.Rapid differentiation of influenza A virus subtypes and genetic screening for virus variants by high-resolution melting analysisCharacterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils.Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes.Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR.Immune responses after live attenuated influenza vaccination.Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View
P2860
Q26783844-2BC8991F-1B2F-4B75-B3EA-63E5AD35B914Q27677202-A4DAB908-E785-4DE3-89B0-A098A88126E6Q27682007-0860C348-E99F-4851-98FE-9AE34EEB68B3Q28388806-361523E8-D365-4509-89A3-6EC60180F847Q34357182-91846209-144F-440A-8DA9-3712E49FE9D7Q34653879-6293851F-B353-4AC7-8C9E-D4C3CF7AD25AQ34976916-B219906A-7306-4743-A7C7-A24754D896E6Q35110968-331CB585-3A2E-45CF-A31A-A19C95EEB304Q36482772-C7FE2BFE-9B0F-40E3-A265-433BCA9067FDQ36497812-B70E81B5-EC65-4BD6-8F75-B8AF8FCC182FQ36509477-5D36773D-96E6-4911-BF56-80B7A25AA0CEQ37161924-AF1AF1D4-132F-481F-AA08-5A248C8BF585Q37596474-40FC3E21-4A6A-495C-9E60-8BF950CF5AD3Q39320513-FC745FE0-0932-4905-AFF9-C5F0D28A74BCQ39732911-EC43A9D2-8A05-477B-BC37-C7F3599836D5Q47937377-BE853951-AFDA-42F7-B7EB-29F8E3086FD6Q56536297-FC03070B-A541-41AF-8067-8C806CE6391F
P2860
Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@ast
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@en
type
label
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@ast
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@en
prefLabel
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@ast
Genotypic stability of cold-ad ...... in an efficacy clinical trial.
@en
P2093
P2860
P1476
Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial
@en
P2093
P2860
P304
P407
P577
2000-02-01T00:00:00Z